A Phase 3 interventional study of FTC/TDF and F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 78 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-12.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the efficacy of switching from emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) fixed dose combination (FDC) to emtricitabine/tenofovir alafenamide (F/TAF) FDC in HIV-1 positive participants who are virologically suppressed on regimens containing FTC/TDF.
This study will consist of a 96 week double-blind treatment period. After Week 96, all participants will continue on blinded study drug treatment and attend visits every 12 weeks until treatment assignments are unblinded. All participants will return for an unblinding visit and will be given the option to receive open-label F/TAF and attend visits every 12 weeks until F/TAF is commercially available, or the sponsor terminates the F/TAF clinical development program.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
Drug: F/TAF · Drug: Allowed third antiretroviral agent · Drug: FTC/TDF Placebo
Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
Drug: FTC/TDF · Drug: Allowed third antiretroviral agent · Drug: F/TAF Placebo
200/300 mg FDC tablets administered orally once daily
Also known as: Truvada®
Drug pages: Emtricitabine · Tenofovir alafenamide
Tablets administered orally once daily
Also known as: Descovy®
An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
Tablets administered orally once daily
Tablets administered orally once daily
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.
Time frame: Baseline; Week 48
Percentage Change From Baseline in Spine BMD at Week 48
Spine BMD was assessed by DXA scan.
Time frame: Baseline; Week 48
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the FDA Snapshot Analysis
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 as Defined by the FDA Snapshot Analysis
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Percentage Change From Baseline in Hip BMD at Week 96
Hip BMD was assessed by DXA scan.
Time frame: Baseline; Week 96
Percentage Change From Baseline in Spine BMD at Week 96
Spine BMD was assessed by DXA scan.
Time frame: Baseline; Week 96
Change From Baseline in CD4+ Cell Count at Week 96
Time frame: Baseline; Week 96
Participants were enrolled at study sites in North America and Europe. The first participant was screened on 06 May 2014. The last study visit occurred on 1 March 2019.
| Milestone | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Started | 334 | 334 |
| Safety analysis set | 333 | 330 |
| Completed | 296 | 300 |
| Not completed | 38 | 34 |
| Withdrew: Randomized but never treated | 1 | 4 |
| Withdrew: Withdrawal by subject | 19 | 16 |
| Withdrew: Lost to follow-up | 7 | 4 |
| Withdrew: Physician decision | 2 | 5 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Non-compliance with study drug | 3 | 1 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Death | 1 | 1 |
| Milestone | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Started | 33 | 31 |
| Completed | 21 | 21 |
| Not completed | 12 | 10 |
| Withdrew: Physician decision | 8 | 8 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis | 94.3 | 93.0 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.
| percentage change | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Percentage Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 | 1.236 ± 2.6602 | -0.071 ± 2.3316 |
Spine BMD was assessed by DXA scan.
| percentage change | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Percentage Change From Baseline in Spine BMD at Week 48 | 1.662 ± 3.1279 | -0.109 ± 3.3476 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis | 91.6 | 90.9 |
| cells/μL | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | 20 ± 161.8 | 21 ± 152.7 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the FDA Snapshot Analysis | 83.5 | 86.1 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 as Defined by the FDA Snapshot Analysis | 88.6 | 89.1 |
Hip BMD was assessed by DXA scan.
| percentage change | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Percentage Change From Baseline in Hip BMD at Week 96 | 1.856 ± 3.2195 | -0.289 ± 2.9912 |
Spine BMD was assessed by DXA scan.
| percentage change | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Percentage Change From Baseline in Spine BMD at Week 96 | 2.159 ± 3.8374 | -0.109 ± 3.6738 |
| cells/μL | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 96 | 50 ± 198.7 | 46 ± 169.4 |
Collected over First dose of study drug to the last dose (maximum: 227.4 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| F/TAF + 3rd Agent (Double-Blind) | 2/333 (0.6%) | 29/333 (8.7%) | 242/333 (72.7%) |
| FTC/TDF + 3rd Agent (Double-Blind) | 1/330 (0.3%) | 31/330 (9.4%) | 226/330 (68.5%) |
| Open-Label F/TAF From F/TAF | 0/33 (0%) | 2/33 (6.1%) | 12/33 (36.4%) |
| Open-Label F/TAF From FTC/TDF | 0/31 (0%) | 3/31 (9.7%) | 13/31 (41.9%) |
| Event | F/TAF + 3rd Agent (Double-Blind) | FTC/TDF + 3rd Agent (Double-Blind) | Open-Label F/TAF From F/TAF | Open-Label F/TAF From FTC/TDF |
|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/333 | 0/330 | 0/33 | 1/31 |
| Enteritis infectiousInfections and infestations | 0/333 | 0/330 | 0/33 | 1/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/333 | 0/330 | 0/33 | 1/31 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/333 | 0/330 | 0/33 | 1/31 |
| Chest painGeneral disorders | 2/333 | 1/330 | 1/33 | 0/31 |
| InfluenzaInfections and infestations | 0/333 | 0/330 | 1/33 | 0/31 |
| LaryngitisInfections and infestations | 0/333 | 0/330 | 1/33 | 0/31 |
| Lung infectionInfections and infestations | 0/333 | 0/330 | 1/33 | 0/31 |
| Prostatitis Escherichia coliInfections and infestations | 0/333 | 0/330 | 1/33 | 0/31 |
| DeliriumPsychiatric disorders | 0/333 | 0/330 | 1/33 | 0/31 |
| Event | F/TAF + 3rd Agent (Double-Blind) | FTC/TDF + 3rd Agent (Double-Blind) | Open-Label F/TAF From F/TAF | Open-Label F/TAF From FTC/TDF |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 54/333 | 67/330 | 1/33 | 0/31 |
| DiarrhoeaGastrointestinal disorders | 44/333 | 42/330 | 1/33 | 0/31 |
| NasopharyngitisInfections and infestations | 43/333 | 27/330 | 4/33 | 2/31 |
| Back painMusculoskeletal and connective tissue disorders | 37/333 | 28/330 | 3/33 | 2/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/333 | 20/330 | 2/33 | 2/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 35/333 | 23/330 | 0/33 | 2/31 |
| HeadacheNervous system disorders | 33/333 | 22/330 | 0/33 | 1/31 |
| OnychomycosisInfections and infestations | 6/333 | 3/330 | 0/33 | 3/31 |
| SinusitisInfections and infestations | 23/333 | 28/330 | 2/33 | 3/31 |
| BronchitisInfections and infestations | 32/333 | 26/330 | 1/33 | 1/31 |
The Safety Analysis Set included all randomized participants who received at least one dose of study drug.
| Age, Continuous(Years) | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent | Total |
|---|---|---|---|
| Mean | 47 ± 9.9 | 48 ± 9.7 | 48 ± 9.8 |
| Sex: Female, Male(Participants) | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent | Total |
|---|---|---|---|
| Female | 48 | 54 | 102 |
| Male | 285 | 276 | 561 |
| Ethnicity (NIH/OMB)(Participants) | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent | Total |
|---|---|---|---|
| Hispanic or Latino | 48 | 78 | 126 |
| Not Hispanic or Latino | 285 | 252 | 537 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 6 | 0 | 6 |
| Black | 69 | 67 | 136 |
| Native Hawaiian or Pacific Islander | 2 | 1 | 3 |
| White | 244 | 253 | 497 |
| Not Permitted | 1 | 1 | 2 |
| Other | 9 | 7 | 16 |
| Region of Enrollment(participants) | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent | Total |
|---|---|---|---|
| Canada | 5 | 9 | 14 |
| Belgium | 3 | 3 | 6 |
| United States | 282 | 274 | 556 |
| Italy | 2 | 6 | 8 |
| United Kingdom | 23 | 17 | 40 |
| France | 18 | 21 | 39 |
| Baseline Third Agent(participants) | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent | Total |
|---|---|---|---|
| Atazanavir boosted with ritonavir (ATV/r) | 53 | 50 | 103 |
| Darunavir boosted with ritonavir (DRV/r) | 84 | 82 | 166 |
| Lopinavir boosted with ritonavir (LPV/r) | 18 | 18 | 36 |
| Dolutegravir (DTG) | 26 | 23 | 49 |
| Efavirenz (EFV) | 8 | 6 | 14 |
| Maraviroc (MVC) | 1 | 6 | 7 |
| Nevirapine (NVP) | 74 | 66 | 140 |
| Raltegravir (RAL) | 66 | 73 | 139 |
| Rilpivirine (RPV) | 3 | 6 | 9 |
| HIV-1 RNA Categories(participants) | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent | Total |
|---|---|---|---|
| < 50 copies/mL | 329 | 326 | 655 |
| >= 50 copies/mL | 4 | 4 | 8 |
| CD4 Cell Count(cells/µL) | F/TAF + 3rd Agent | FTC/TDF + 3rd Agent | Total |
|---|---|---|---|
| Mean | 691 ± 272.6 | 667 ± 272.3 | 679 ± 272.5 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from May 2014 to primary completion in Aug 2015, 15 months.
Results were first posted in Nov 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Emtricitabine · Tenofovir alafenamide